Health & Fitness
Mon, September 13, 2010Sun, September 12, 2010Fri, September 10, 2010Thu, September 9, 2010Wed, September 8, 2010Tue, September 7, 2010Sat, September 4, 2010Fri, September 3, 2010Thu, September 2, 2010Wed, September 1, 2010Tue, August 31, 2010Mon, August 30, 2010Sun, August 29, 2010Fri, August 27, 2010Thu, August 26, 2010Wed, August 25, 2010Tue, August 24, 2010Mon, August 23, 2010Fri, August 20, 2010Thu, August 19, 2010Wed, August 18, 2010InSite Vision to Present at Rodman & Renshaw 12th Annual Healthcare Conference
Published in Health and Fitness on Wednesday, September 1st 2010 at 16:25 GMT by Market Wire
ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB: INSV), a company developing novel ophthalmic therapeutics, announced today that Louis Drapeau, Interim Chief Executive Officer, Vice President and Chief Financial Officer, will present a corporate overview at the upcoming Rodman & Renshaw 12th Annual Healthcare Conference. The conference is being held September 12-15, 2010 at the New York Palace Hotel in New York City.
Mr. Drapeaua™s presentation is scheduled for Monday, September 13, 2010 at 10:50 am EDT. Mr. Drapeau will discuss InSitea™s commercial products and partnerships; the companya™s proprietary DuraSite® bioadhesive polymer platform technology; and InSitea™s emerging pipeline, including the recent advancement of ISV-303 into Phase 1/2 clinical trials for the treatment of ocular pain.
The presentation will also be webcast and available on the Investor Relations page of the company's website at [ www.insitevision.com ]. The presentation will be archived for replay at the same address one hour after conclusion of the live event for a period of 30 days.
About InSite Vision
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The companya™s product portfolio utilizes InSite Visiona™s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivancea" (besifloxacin ophthalmic suspension) 0.6%, marketed by InSite Visiona™s licensee Bausch & Lomb and their partner Pfizer Inc. InSite Visiona™s clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, and ISV-303 for pain and swelling associated with ocular surgery. For further information on InSite Vision, please visit [ www.insitevision.com ].
